This site is intended for healthcare professionals

Magnifying glass on blue background; searching for results

Find disease awareness content and relevant supporting materials

Learning Zone 508 Events 5 News 20291 Drugs 42790 Trials 863 Guidelines 631 Journals 1966

Blue test tubes arranged in a line, disappearing into the background

Acoramidis reduced incidence of atrial fibrillation events in patients with ATTR-CM- BridgeBio Pharma

5 min read

Blue test tubes arranged in a line, disappearing into the background

NICE (UK) terminated appraisal for Skyclarys (omaveloxolone) for treating Friedreich’s ataxia in people 16 years and over - Biogen

1 min read

Blue test tubes arranged in a line, disappearing into the background

BATURA Phase III trial results provide new evidence for Airsupra as standard of care for as-needed rescue treatment in asthma - AstraZeneca

4 min read

Blue test tubes arranged in a line, disappearing into the background

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

1 min read

Blue test tubes arranged in a line, disappearing into the background

Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma- GSK

5 min read

Blue test tubes arranged in a line, disappearing into the background

FDA approves Welireg (belzutifan) for the treatment of adults and pediatric patients with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL) - Merck Inc

2 min read

Blue test tubes arranged in a line, disappearing into the background

Alnylam to share progress across its transthyretin amyloidosis franchise including additional analyses of the HELIOS-B phase III Study Results at Heart Failure 2025 Congress

1 min read

Blue test tubes arranged in a line, disappearing into the background

European Commission approves Tremfya (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease - Johnson & Johnson

4 min read

Blue test tubes arranged in a line, disappearing into the background

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine - Eli Lilly

3 min read

Blue test tubes arranged in a line, disappearing into the background

Xtandi (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Astellas and Pfizer

4 min read